Challenges in the electrophysiology and Watchman businesses led Boston Scientific to cut its sales and earnings per share forecasts for the second quarter in a row.[6192477] The company plans to restructure, taking up to $800M in charges, following a slowdown in two of its key product lines.[6029426]